GRAIL, Inc.

GRAIL, Inc.

GRAL·NASDAQ

$66.93

+9.5%
HealthcareMedical - Diagnostics & Research

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

At a Glance

Live Snapshot
Market Cap$2.87B
EPS-11.1100
P/E Ratio-6.02
Earnings Date08/11/2026

gral

Property, Plant, and Equipment (Net)

Last Annual Value

103.88M

3-Year CAGR

-19%

5-Year CAGR

%

10-Year CAGR

12%

GRAIL, Inc.

GRAIL, Inc. Competitors Analysis of Property, Plant, and Equipment (Net)

GRAL · NASDAQ
CompanyProperty, Plant, and Equipment (Net)
CAGR 3Y
CAGR 5Y
CAGR 10Y
GRAL logo
GRAIL, Inc.
NASDAQ:GRAL
103.88M
-15.0%-13.6%N/A 
2.38M
78.3%39.2%36.9%
CELC logo
Celcuity Inc.
NASDAQ:CELC
550.00K
-4.4%-0.2%14.3%
267.00M
-2.8%8.7%31.7%
438.90M
0.3%2.3%N/A
14.38M
77.0%N/AN/A
31.29M
54.9%29.3%N/A
44.77M
10.3%1.8%-39.8%
GRAIL, Inc.

GRAIL, Inc. Fair Value Envelope

GRAL · NASDAQ

Our analysis suggests that GRAL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $66.9343, this represents a potential HIDDEN relative to our calculated worth for GRAIL, Inc..

Intrinsic Value
Current Price: $66.9343